Based on moderate quality evidence , due to concerns about risk of bias and imprecision , initiation of statin therapy within 14 days following ACS does not reduce death , myocardial infa rct ion , or stroke up to four months , but reduces the occurrence of unstable angina at four months following ACS .
Serious side effects were rare
BACKGROUND The early period following the onset of acute coronary syndrome ( ACS ) represents a critical stage of coronary heart disease , with a high risk of recurrent events and deaths .
The short-term effects of early treatment with statins on patient-relevant outcomes in patients suffering from ACS are unclear .
This is an up date of a review previously published in 2011 .
OBJECTIVES To assess the effects , both harms and benefits , of early administered statins in patients with ACS , in terms of mortality and cardiovascular events .
The effect of early treatment by cerivastatin on the serum level of C-reactive protein, interleukin-6, and interleukin-8 in patients with unstable angina and non-Q-wave myocadial infarction
The aim of our study was to evaluate whether a single dose of cerivastatin at the time of admission of patients with unstable angina pectoris ( UAP ) or non-Q-wave myocardial infa rct ion ( NQMI ) can influence the serum level of C-reactive protein ( CRP ) , interleukin-6 ( IL-6 ) and interleukin-8 ( IL-8 ) 24 h later . Forty-four patients with rest chest pain and subendocardial ischemia on ECG were r and omized to receive cerivastatin 0.3 mg at the time of admission ( group C+ ) to st and ard therapy or to remain just on st and ard therapy ( group C− ) . Blood sample s for determination of troponin I ( TI ) , CRP , IL-6 and IL-8 were collected at admission ( entry level ) and 24 h later ( final level ) . Patients with non-physiological baseline levels of TI  , as well as patients with progression to Q wave MI were excluded . All baseline , clinical and demographic data and final values of TI were comparable in the two groups . In patients treated with cerivastatin ( group C+ , n = 13 ) we observed decrease in the CRP level ( −6.73 ± 3.93 mg/L ) ; on the other h and , in group C− ( n = 17 ) the CRP level increased ( + 7.92 ± 2.77 mg/L , p = 0.004 ) . Similar differences were observed also in IL-6 : in group C+ the level was significantly reduced as compared with the increase in group C− ( −0.76 ± 0.52 vs. 4.58 ± 1.49 ng/L , p = 0.005 ) . The level of IL-8 was not affected . Our results suggest that early treatment with cerivastatin can decrease the serum level of CRP and IL-6 in patients with UAP/NQMI ; this might positively influence their prognosis . Nevertheless , further studies are needed to support this hypothesis
Based on moderate quality evidence , due to concerns about risk of bias and imprecision , initiation of statin therapy within 14 days following ACS does not reduce death , myocardial infa rct ion , or stroke up to four months , but reduces the occurrence of unstable angina at four months following ACS .
Serious side effects were rare
BACKGROUND The early period following the onset of acute coronary syndrome ( ACS ) represents a critical stage of coronary heart disease , with a high risk of recurrent events and deaths .
The short-term effects of early treatment with statins on patient-relevant outcomes in patients suffering from ACS are unclear .
This is an up date of a review previously published in 2011 .
OBJECTIVES To assess the effects , both harms and benefits , of early administered statins in patients with ACS , in terms of mortality and cardiovascular events .